Get access

Substantial improvement in a Meige's syndrome patient with levetiracetam treatment

Authors

  • Theresa A. Zesiewicz MD,

    Corresponding author
    1. Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA
    2. Department of Neurology, University of South Florida, Tampa, Florida, USA
    • 12901 Bruce B. Downs Blvd., MDC Box 55, Tampa, FL 33612
    Search for more papers by this author
  • Elan D. Louis MD, MS,

    1. GH Sergievsky Center and Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York, USA
    Search for more papers by this author
  • Kelly L. Sullivan MSPH,

    1. Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA
    2. Department of Neurology, University of South Florida, Tampa, Florida, USA
    Search for more papers by this author
  • Martin Menkin MD,

    1. Orlando Center for Neurology, Orlando Regional Medical Center, Florida Hospital, Orlando, Florida, USA
    Search for more papers by this author
  • Peter B. Dunne MD,

    1. Department of Neurology, University of South Florida, Tampa, Florida, USA
    Search for more papers by this author
  • Robert A. Hauser MD

    1. Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA
    2. Department of Neurology, University of South Florida, Tampa, Florida, USA
    3. Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA
    Search for more papers by this author

Abstract

We report on a woman with idiopathic Meige's syndrome whose dystonia improved with the use of levetiracetam (LEV, Keppra, UCB Pharma, Smyrna, GA). This report and data from an animal model of paroxysmal dystonia suggest that LEV might be helpful in the treatment of dystonia. © 2004 Movement Disorder Society

Ancillary